BioLineRx
From Wikipedia, the free encyclopedia
BioLineRx Ltd. (Hebrew: ביוליין אר אקס), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
| |
| Company type | Public |
|---|---|
| Nasdaq: BLRX TASE: BLRX | |
| Industry | Biotechnology |
| Founded | 2003 |
| Headquarters | , Israel |
Key people | Philip Serlin (CEO) |
| Services | Drug development |
| Owners | Novartis (12.8%, 2014) |
| Website | www |
| Footnotes / references [1][2] | |
Corporate history
The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.[3] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.[4][5] In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.[6][7] In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C.[8] At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.[2]
Management
Morris Laster, (M.D.) an alumnus of. Downstate Medical Center, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University early in 2010.[9] Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.
Operations
BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs.[10] The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.[11] In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.[12]
Pipeline
Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.
- BL-1010 – orally available neuropathic pain[13]
- BL-1020 – orally available GABA-enhanced antipsychotic for treatment of schizophrenia[14]
- BL-1021 – orally available small molecule for treatment of neuropathic pain[15]
- BL-1040 – liquid polymer injected into patients with acute myocardial infarction, invented by Smadar Cohen of Ben-Gurion University[16][17]
- BL-1230 - a selective cannabinoid receptor type 2 (CB2R) agonist for Dry Eye Syndrome (DES) [18]
- BL-5010 – cream treatment for seborrheic keratosis skin lesions[19]
- BL-7040 – orally available anti-inflammatory drug invented by Hermona Soreq of the Hebrew University of Jerusalem[20]
- BL-8020 – orally administered treatment for Hepatitis C, developed by Philippe Halfon, co-founder and President of Genoscience.
- BL-8030 – second-generation NS3 protease inhibitor for oral treatment of Hepatitis C, invented by Philippe Halfon[21]